The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 21, 2025

Filed:

Nov. 11, 2019
Applicant:

West China Hospital, Sichuan University, Sichuan, CN;

Inventors:

Yongsheng Wang, Sichuan, CN;

Qizhi Ma, Sichuan, CN;

Dan Li, Sichuan, CN;

Qiyu Yang, Sichuan, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2005.12); A61P 35/04 (2005.12); C07K 16/28 (2005.12); C07K 16/30 (2005.12); C07K 16/32 (2005.12); A61K 39/00 (2005.12);
U.S. Cl.
CPC ...
C07K 16/2827 (2012.12); A61P 35/04 (2017.12); C07K 16/2863 (2012.12); C07K 16/30 (2012.12); C07K 16/32 (2012.12); A61K 2039/507 (2012.12); C07K 2317/622 (2012.12); C07K 2319/02 (2012.12); C07K 2319/03 (2012.12); C07K 2319/33 (2012.12); C07K 2319/50 (2012.12);
Abstract

The present invention belongs to the field of genetic engineering, and particularly relates to a genetically engineered dual-targeting chimeric antigen receptor. The present invention provides a genetically engineered dual-targeting chimeric antigen receptor and a host cell thereof in response to up-regulated expression of PD-L1 in tumor cells and immune cells after these cells are exposed to malignant serosal cavity effusion. The dual-targeting chimeric antigen receptor provided by the present invention competitively binds to PD-L1 to transform an inhibition signal of PD-L1 into an activation signal and to enhance the killing activity of T cells; meanwhile, 4-1BB introduced downstream thereof can promote proliferation and survival of T cells. In addition, the present invention also discloses a host cell expressing the above dual-targeting antigen receptor and a use thereof in preventing or treating solid tumors.


Find Patent Forward Citations

Loading…